skip to Main Content
Newsfeed image, light gray text on dark gray background

VIDEO: Niraparib-Ipilimumab Maintenance Prevents Advanced Pancreatic Cancer Progression

Maintenance with niraparib (Zejula, GlaxoSmithKine) plus ipilimumab (Yervoy, Bristol Myers Squibb) was effective in preventing progression in patients with advanced pancreatic cancer and led to a PFS of approximately 8 months, Reiss, assistant professor of medicine at the Hospital of the University of Pennsylvania, said. In comparison, niraparib plus nivolumab (Opdivo, Bristol Myers Squibb) was…

Newsfeed image, light gray text on dark gray background

Researchers Identify New Cell Subtype in Early-Stage Pancreatic Cancer

In a recent paper published in Frontiers in Physiology, the researchers used histopathological analyses, genetically engineered animal models and human samples to quantify the subtypes of EECs throughout the development of pancreatic tumors. This work acknowledged the diversity within this cell population and sought to understand how different quantities of each EEC subtype could contribute to disease progression. Read…

Newsfeed image, light gray text on dark gray background

The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival

Individuals recommended for pancreas surveillance were prospectively enrolled into one of eight CAPS5 study centers between 2014 and 2021. The primary end point was the stage distribution of pancreatic ductal adenocarcinoma (PDAC) detected (stage I v higher-stage). Overall survival was determined using the Kaplan-Meier method. Read more . . . 

Newsfeed image, light gray text on dark gray background

Targetable Landscape in Pancreatic Cancer Varies Greatly by KRAS Status

Homologous recombination deficiency, high tumor mutation burden and microsatellite instability-high disease also appeared more common in the KRAS wild-type population.In addition, early-onset pancreatic cancers — those diagnosed before age 50 years — appeared more likely to be KRAS wild-type, exhibit homologous recombination deficiency phenotype and have germline BRCA1/BRCA2 alterations.  Read more . . . 

Newsfeed image, light gray text on dark gray background

Exercise Slows Tumor Growth in Pancreatic Cancer

“Our findings show, for the first time, how aerobic exercise affects the immune microenvironment within pancreatic tumors,” noted lead author Emma Kurz, MD, PhD, from at the NYU Grossman School of Medicine, New York. Read more . . . 

Newsfeed image, light gray text on dark gray background

Dr. Botta on the Evaluation of CT041 in Gastric and Pancreatic Cancer

In the open label, multi-center study, investigators evaluated CT041, a CAR T-cell therapy that targets Claudin18.2 (CLDN18.2).Heavily pretreated patients in the population were able to achieve responses up to 60% in the salvage line setting, Botta says. Moreover, patients who have been on multiple lines of chemotherapy and present with various comorbidities were able to…

Back To Top